Wu Yi-Long相关文献与解析，生知库 | 链接生命科学的每一步

Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study

帕博利珠单抗与化疗治疗中国非小细胞肺癌且程序性死亡配体1肿瘤比例评分≥1%患者的五年疗效：KEYNOTE-042中国研究

Wu, Yi-Long; Zhang, Li; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Arenas, Carmen González; Chen, Zhenghong; Yu, Wen Cheng; Mok, Tony S K

肺癌

Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China

中国一项前瞻性观察性真实世界研究，评估阿法替尼一线治疗表皮生长因子受体（EGFR）突变阳性晚期非小细胞肺癌（NSCLC）患者的疗效。

期刊:Lung Cancer: Targets and Therapy

影响因子:3.3

doi:10.2147/LCTT.S555262

Zhou, Jianying; Wang, Yongsheng; Peng, Jiewen; Tang, Ke-Jing; Wu, Jun; Chen, Yajuan; Xue, Zhiyi; Wu, Yi-Long

Neoadjuvant afatinib in a patient with locally advanced lung adenocarcinoma harboring an NPTN-NRG1 fusion: a case report

NPTN-NRG1融合基因阳性局部晚期肺腺癌患者新辅助阿法替尼治疗：病例报告

期刊:World Journal of Surgical Oncology

影响因子:2.5

doi:10.1186/s12957-026-04233-6

Zhou, Chu-Yu; Xu, Zi-Yi; Qiu, Zhen-Bin; Wang, Fei; Li, Hong-Ji; Liao, Ri-Qiang; Wu, Yi-Long; Zhong, Wen-Zhao

SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

SAFFRON-301：一项随机III期研究，评估sitravatinib联合tislelizumab治疗局部晚期或转移性非小细胞肺癌患者的疗效

期刊:

影响因子:

doi:10.1136/bmjonc-2025-000890

Zhou, Qing; Gao, Bo; Hu, Jie; Zhao, Jun; Wang, Mengzhao; He, Kai; Zhang, Wei; Liu, Chunling; Fang, Jian; Li, Xing Ya; Wang, Zhehai; Matos, Marco; Kwatra, Vineet; Zheng, Wenjuan; Wang, Chenyang; Chen, Yaxi; Zhang, Juan; Wang, Jun; Wu, Yi-Long

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

EGFR突变型IB-IIIA期非小细胞肺癌切除术后辅助奥希替尼治疗的分子残留病灶分析

期刊:Nature Medicine

影响因子:50

doi:10.1038/s41591-025-03577-y

Herbst, Roy S; John, Thomas; Grohé, Christian; Goldman, Jonathan W; Kato, Terufumi; Laktionov, Konstantin; Bonanno, Laura; Tiseo, Marcello; Majem, Margarita; Dómine, Manuel; Ahn, Myung-Ju; Kowalski, Dariusz M; Pérol, Maurice; Sriuranpong, Virote; Özgüroğlu, Mustafa; Bhetariya, Preetida; Markovets, Aleksandra; Rukazenkov, Yuri; Muldoon, Caitlin; Robichaux, Jacqulyne; Hartmaier, Ryan; Tsuboi, Masahiro; Wu, Yi-Long

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study

HER2选择性酪氨酸激酶抑制剂Zongertinib（BI 1810631）治疗HER2改变的晚期/转移性实体瘤患者：一项Ia期剂量递增研究

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO-24-01727

Heymach, John V; Opdam, Frans; Barve, Minal; Tu, Hai-Yan; Wu, Yi-Long; Berz, David; Schröter, Lukas; Botilde, Yanick; Sadrolhefazi, Behbood; Serra, Josep; Yoh, Kiyotaka; Yamamoto, Noboru

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

在III期EXCLAIM-2试验中，一线Mobocertinib与铂类化疗在EGFR 20号外显子插入阳性转移性非小细胞肺癌患者中的疗效比较

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO-24-01269

Jänne, Pasi A; Wang, Bin-Chao; Cho, Byoung Chul; Zhao, Jun; Li, Juan; Hochmair, Maximilian; Peters, Solange; Besse, Benjamin; Pavlakis, Nick; Neal, Joel W; Kato, Terufumi; Wu, Yi-Long; Nguyen, Danny; Lin, Junjing; Lin, Jianchang; Vranceanu, Florin; Szumski, Annette; Lin, Huamao M; Fram, Robert J; Mok, Tony S K

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

一项针对接受 EGFR-TKI 治疗后出现渐进性、寡转移性或潜在进展的晚期非小细胞肺癌患者的 II 期试验，评估安罗替尼联合 EGFR-TKI 的疗效 (CTONG-1803/ALTER-L001)

期刊:Journal of Hematology & Oncology

影响因子:40.4

doi:10.1186/s13045-024-01656-0

Chen, Hua-Jun; Tu, Hai-Yan; Hu, Yanping; Fan, Yun; Wu, Guowu; Cang, Shundong; Yang, Yi; Yang, Nong; Ma, Rui; Jin, Gaowa; Xu, Ximing; Liu, Anwen; Tang, Shubin; Cheng, Ying; Yu, Yan; Xu, Chong-Rui; Zhou, Qing; Wu, Yi-Long

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

PACIFIC-5：一项针对不可切除的 III 期非小细胞肺癌患者，在同步或序贯放化疗后未出现疾病进展的情况下，进行度伐利尤单抗巩固治疗的 III 期临床试验

期刊:Journal of Hematology & Oncology

影响因子:40.4

doi:10.1186/s13045-025-01768-1

Wu, Yi-Long; Wu, Lin; Bi, Nan; Cil, Timucin; Ge, Hong; Zhu, Zhengfei; Wang, Chih-Liang; Zhang, Wei; Lv, Dongqing; Mingyan, E; Sun, Jianguo; Pan, Yi; Krzakowski, Maciej; Dikilitas, Mustafa; Sendur, Mehmet Ali Nahit; Kim, Young-Chul; Yang, Yanjiao; Mao, Rui; Zhang, Biao; Wang, Luhua

Current and future immunotherapies for NSCLC

目前和未来针对非小细胞肺癌的免疫疗法

Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study

帕博利珠单抗与化疗治疗中国非小细胞肺癌且程序性死亡配体1肿瘤比例评分≥1%患者的五年疗效：KEYNOTE-042中国研究

Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China

中国一项前瞻性观察性真实世界研究，评估阿法替尼一线治疗表皮生长因子受体（EGFR）突变阳性晚期非小细胞肺癌（NSCLC）患者的疗效。

Neoadjuvant afatinib in a patient with locally advanced lung adenocarcinoma harboring an NPTN-NRG1 fusion: a case report

NPTN-NRG1融合基因阳性局部晚期肺腺癌患者新辅助阿法替尼治疗：病例报告

SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

SAFFRON-301：一项随机III期研究，评估sitravatinib联合tislelizumab治疗局部晚期或转移性非小细胞肺癌患者的疗效

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

EGFR突变型IB-IIIA期非小细胞肺癌切除术后辅助奥希替尼治疗的分子残留病灶分析

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study

HER2选择性酪氨酸激酶抑制剂Zongertinib（BI 1810631）治疗HER2改变的晚期/转移性实体瘤患者：一项Ia期剂量递增研究

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

在III期EXCLAIM-2试验中，一线Mobocertinib与铂类化疗在EGFR 20号外显子插入阳性转移性非小细胞肺癌患者中的疗效比较

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

一项针对接受 EGFR-TKI 治疗后出现渐进性、寡转移性或潜在进展的晚期非小细胞肺癌患者的 II 期试验，评估安罗替尼联合 EGFR-TKI 的疗效 (CTONG-1803/ALTER-L001)

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

PACIFIC-5：一项针对不可切除的 III 期非小细胞肺癌患者，在同步或序贯放化疗后未出现疾病进展的情况下，进行度伐利尤单抗巩固治疗的 III 期临床试验